医用产品

Search documents
瑞迈特股价涨5.28%,华泰柏瑞基金旗下1只基金重仓,持有13.69万股浮盈赚取59.96万元
Xin Lang Cai Jing· 2025-10-16 03:50
10月16日,瑞迈特涨5.28%,截至发稿,报87.33元/股,成交9744.09万元,换手率2.03%,总市值78.25 亿元。 截至发稿,方纬累计任职时间11年59天,现任基金资产总规模21.27亿元,任职期间最佳基金回报 260.51%, 任职期间最差基金回报-17.22%。 资料显示,北京瑞迈特医疗科技股份有限公司位于北京市丰台区丽泽路16号院4号楼北京汇亚大厦17层 10号,成立日期2001年7月27日,上市日期2022年11月1日,公司主营业务涉及研发、生产、销售呼吸健 康领域医疗设备与耗材产品及相关服务,为以阻塞型睡眠呼吸暂停低通气综合征(OSA)为主的睡眠呼吸暂 停低通气综合征(SAHS)患者以及以慢性阻塞性肺疾病(COPD)为主的呼吸功能不全(Respiratory Insufficiency)患者提供全周期(从诊断、治疗到慢病管理)、多场景(从医疗机构到家庭)的治疗服务整体解 决方案。主营业务收入构成为:家用呼吸诊疗产品64.19%,耗材32.67%,医用产品3.05%,其他 0.10%。 风险提示:市场有风险,投资需谨慎。本文为AI大模型自动发布,任何在本文出现的信息(包括但不 限于个股 ...
瑞迈特10月10日获融资买入1219.67万元,融资余额1.08亿元
Xin Lang Cai Jing· 2025-10-13 01:41
截至6月30日,瑞迈特股东户数6850.00,较上期减少24.87%;人均流通股8251股,较上期增加33.11%。 2025年1月-6月,瑞迈特实现营业收入5.44亿元,同比增长42.30%;归母净利润1.31亿元,同比增长 42.19%。 分红方面,瑞迈特A股上市后累计派现2.28亿元。 机构持仓方面,截止2025年6月30日,瑞迈特十大流通股东中,香港中央结算有限公司退出十大流通股 东之列。 责任编辑:小浪快报 10月10日,瑞迈特涨2.91%,成交额1.23亿元。两融数据显示,当日瑞迈特获融资买入额1219.67万元, 融资偿还919.60万元,融资净买入300.07万元。截至10月10日,瑞迈特融资融券余额合计1.09亿元。 融资方面,瑞迈特当日融资买入1219.67万元。当前融资余额1.08亿元,占流通市值的2.25%,融资余额 超过近一年50%分位水平,处于较高位。 融券方面,瑞迈特10月10日融券偿还0.00股,融券卖出0.00股,按当日收盘价计算,卖出金额0.00元; 融券余量8100.00股,融券余额68.47万元,低于近一年40%分位水平,处于较低位。 资料显示,北京瑞迈特医疗科技股份有 ...
瑞迈特涨2.04%,成交额4251.75万元,主力资金净流出135.50万元
Xin Lang Cai Jing· 2025-09-24 06:09
Core Viewpoint - The stock price of Ruimait has shown a significant increase of 35.98% year-to-date, despite recent declines in the short term, indicating volatility in the market [2]. Company Overview - Ruimait Medical Technology Co., Ltd. specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The company was established on July 27, 2001, and went public on November 1, 2022 [2]. - The revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. Financial Performance - For the first half of 2025, Ruimait reported a revenue of 544 million yuan, representing a year-on-year growth of 42.30%, and a net profit attributable to shareholders of 131 million yuan, also reflecting a growth of 42.19% [3]. - As of June 30, 2025, the number of shareholders decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [3]. Market Activity - On September 24, Ruimait's stock price rose by 2.04% to 85.13 yuan per share, with a trading volume of 42.52 million yuan and a turnover rate of 0.89%, resulting in a total market capitalization of 7.628 billion yuan [1]. - The net outflow of main funds was 1.355 million yuan, with large orders accounting for 10.85% of purchases and 14.03% of sales [1]. Shareholder and Dividend Information - Since its A-share listing, Ruimait has distributed a total of 228 million yuan in dividends [4]. - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [4].
瑞迈特股价连续4天下跌累计跌幅6.36%,诺德基金旗下1只基金持1.8万股,浮亏损失10.46万元
Xin Lang Cai Jing· 2025-09-22 07:20
Group 1 - The core viewpoint of the news is that Ruimait has experienced a decline in stock price, with a cumulative drop of 6.36% over four consecutive days, currently trading at 85.52 yuan per share [1] - Ruimait Medical Technology Co., Ltd. specializes in the research, production, and sales of medical devices and consumables in the respiratory health field, primarily serving patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The company's main business revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - According to data, Nord Fund holds a significant position in Ruimait, with its Nord Small and Mid-Cap Mixed Fund (570006) owning 18,000 shares, accounting for 5.02% of the fund's net value [2] - The fund has incurred a floating loss of approximately 10.46 million yuan during the four-day decline [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a return of 45% year-to-date, ranking 1247 out of 8244 in its category [2]
瑞迈特(301367):25Q2收入环比持续改善,欧美市场表现亮眼
GOLDEN SUN SECURITIES· 2025-09-11 01:03
Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company has shown continuous improvement in revenue quarter-on-quarter, with significant growth in the US and European markets. The inventory destocking cycle in the US has ended, and the European market has begun to enter mainstream medical insurance markets. Domestic market adjustments are showing initial results, leading to dual growth in revenue and profit in Q2 2025 [2][4] - The company’s new noise-reducing cotton ventilator has been launched in the US market, with expectations for increased volume in the second half of the year. The company is deepening its localization strategy overseas, enhancing its global competitiveness [2][3] Financial Performance - In H1 2025, the company achieved operating revenue of 544 million yuan, a year-on-year increase of 42.30%, and a net profit attributable to the parent company of 131 million yuan, also up 42.19%. In Q2 2025, revenue reached 279 million yuan, growing 46.54% year-on-year, with a net profit of 59.41 million yuan, up 39.92% [1][4] - The company’s gross margin in Q2 2025 was 54.64%, an increase of 2.98 percentage points year-on-year. The sales expense ratio decreased by 1.82 percentage points to 12.75%, while the management expense ratio fell by 3.20 percentage points to 6.65% [2] Business Segments - The company’s main business lines showed strong growth in H1 2025: - Home respiratory therapy products generated revenue of 349 million yuan, up 51.49% year-on-year, with a gross margin of 45.02% - Consumables generated revenue of 178 million yuan, up 30.26%, with a gross margin of 65.83% - Medical products generated revenue of 16.56 million yuan, up 12.96%, with a gross margin of 55.77% [3] - Domestic revenue reached 191 million yuan in H1 2025, a year-on-year increase of 16.87%, while overseas revenue was 353 million yuan, up 61.33% [4] Market Outlook - The company is expected to see revenue growth of 27.7%, 22.6%, and 21.2% for the years 2025, 2026, and 2027, respectively, with net profits projected to grow by 76.0%, 31.5%, and 23.0% in the same years [4]
宜安科技业绩双降、利润同比-919%由盈转亏毛利率持续下滑
Xin Lang Cai Jing· 2025-09-05 10:42
Core Insights - The company, Yian Technology, is facing significant structural challenges despite appearing to seek breakthroughs through product innovation in the new materials sector [1] - The operating performance reflected in the 2025 semi-annual report reveals deeper issues beyond surface-level product advancements [1] Financial Performance - In the first half of 2025, the company's operating revenue was 722 million yuan, a year-on-year decrease of 7.0% [2] - The net profit attributable to the parent company was a loss of 18.68 million yuan, representing a year-on-year decline of 919.3% [2] Business Dynamics - There is a disconnect between the core business and new growth points, leading to weakened cash flow and wavering strategic focus [2] - The main products, such as magnesium alloys, are facing long-term profit margin compression due to intensified market competition and increased bargaining pressure from end customers, resulting in continuous shrinkage of gross profit levels [2] Resource Allocation Issues - The mismatch between R&D and market resources is becoming increasingly evident, despite ongoing investments in technological upgrades [2] - The industrialization cycle and market demand rhythm are misaligned, while the high conversion costs of emerging businesses further squeeze overall performance [2] Cash Flow Concerns - The company's cash flow from operating activities has significantly weakened, indicating a declining profitability conversion rate [2] - The deterioration in collection capabilities is a primary factor contributing to cash flow issues [2] Management Stability - Frequent changes in management may pose potential risks to strategic continuity [2] - Recent adjustments in executive positions reflect a phase of instability in governance structure, which could impact the execution consistency during the critical transformation period [2]
瑞迈特涨2.09%,成交额6482.69万元,主力资金净流入26.03万元
Xin Lang Cai Jing· 2025-09-05 04:17
Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established on July 27, 2001, and went public on November 1, 2022. The company specializes in the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with Obstructive Sleep Apnea Syndrome (OSA) and Chronic Obstructive Pulmonary Disease (COPD) [2] Business Performance - For the first half of 2025, the company achieved operating revenue of 544 million yuan, representing a year-on-year growth of 42.30%. The net profit attributable to the parent company was 131 million yuan, also reflecting a year-on-year increase of 42.19% [2] - The revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] Stock Performance - On September 5, the stock price of Ruimait increased by 2.09%, reaching 88.75 yuan per share, with a trading volume of 64.83 million yuan and a turnover rate of 1.31%. The total market capitalization is 7.952 billion yuan [1] - Year-to-date, the stock price has risen by 41.77%, while it has decreased by 2.24% over the last five trading days and by 3.75% over the last twenty days [1] Shareholder Information - As of June 30, 2025, the number of shareholders was 6,850, a decrease of 24.87% from the previous period. The average number of circulating shares per person increased by 33.11% to 8,251 shares [2] - Since its A-share listing, the company has distributed a total of 228 million yuan in dividends [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [3]
采纳股份股价微跌0.57% 子公司获三项专利证书
Jin Rong Jie· 2025-08-20 18:34
Core Viewpoint - The stock price of Canar Medical Co., Ltd. closed at 24.22 yuan on August 20, 2025, reflecting a decrease of 0.14 yuan or 0.57% from the previous trading day [1] Company Overview - Canar Medical operates in the medical device sector, focusing on the research, production, and sales of medical products, veterinary products, and laboratory consumables [1] - In the 2024 annual report, medical products accounted for 51.23% of the company's revenue, while veterinary products made up 39.03% [1] Recent Developments - On August 20, 2025, Canar Medical announced that its wholly-owned subsidiary, Jiangsu Canar Medical Technology Co., Ltd., received three utility model patent certificates from the National Intellectual Property Administration. The patents include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe," all of which are related to the company's main business products [1] Financial Performance - On August 20, 2025, the main funds experienced a net outflow of 716,700 yuan, with a cumulative net outflow of 4,222,500 yuan over the past five days [1]
采纳股份:取得3项专利证书
Mei Ri Jing Ji Xin Wen· 2025-08-20 08:39
Group 1 - The core point of the article is that Canar Medical Technology Co., Ltd., a wholly-owned subsidiary of Canar Co., has recently received patent certificates from the National Intellectual Property Administration for three medical products [2] - The patents granted include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe" [2] - For the fiscal year 2024, Canar's revenue composition is as follows: medical products account for 51.23%, veterinary products for 39.03%, laboratory consumables for 7.61%, and others for 2.13% [2]
普门科技收盘上涨2.73%,滚动市盈率21.55倍,总市值62.90亿元
Sou Hu Cai Jing· 2025-08-15 12:34
Company Overview - Pumen Technology specializes in the research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The main products include medical products, home products, testing equipment, and testing reagents [2] Recent Achievements - In January 2024, Pumen Technology was awarded the "Smart Health and Elderly Care Application Pilot Demonstration - Demonstration Enterprise" by three ministries [2] - The project "Micro-tube Inner Surface Wear-resistant Superhydrophobic Coating and Its Application in Medical Devices" won the "2023 China Corrosion and Protection Society Science and Technology Award" first prize [2] - The subsidiary Guangdong Pumen Biomedical Technology Co., Ltd. was recognized as a "Specialized, Refined, Characteristic, and Innovative Small and Medium-sized Enterprise" by the Guangdong Provincial Department of Industry and Information Technology [2] - A collaborative project with Chongqing University on "Key Technology Development and Industrialization of Fully Automatic Specific Protein Analyzer" received the "2023 China Industry-University-Research Cooperation Innovation Achievement Award" second prize [2] Financial Performance - In Q1 2025, the company reported revenue of 215 million yuan, a year-on-year decrease of 29.69% [2] - Net profit for the same period was 53.68 million yuan, down 49.93% year-on-year [2] - The sales gross margin stood at 64.97% [2] Market Position - As of August 15, Pumen Technology's stock closed at 14.68 yuan, with a PE ratio of 21.55, marking a new low in 92 days [1] - The company's total market capitalization is 6.29 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 56.58 and a median of 39.97, Pumen Technology ranks 45th [1][3] Shareholder Information - As of March 31, 2025, Pumen Technology had 13,289 shareholders, an increase of 3,464 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]